Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early promising results in malaria vaccine trial in Mali

24.01.2008
WHAT: A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.

The trial was the first to test this vaccine candidate, which is designed to block the malaria parasite from entering human blood cells, in a malaria-endemic country. Based on these promising results, the research team is now conducting trials of this vaccine in 400 Malian children aged 1 to 6 years.

Malaria is a leading killer in Africa and other developing countries, claiming more than 1 million lives each year, most of them children.

Lead investigator Mahamadou A. Thera M.D., MPH, and 16 other co-authors of the newly published study are based at the Malaria Research and Training Center at the University of Bamako, Mali. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, supported the trial and helps fund the Center. University of Maryland School of Medicine researcher Christopher Plowe, M.D., MPH, was the co-leader of the study.

The trial enrolled volunteers living in Bandiagara, a rural town in northeast Mali with a heavy burden of malaria. In this relatively dry region, almost no new infections occur during the driest month of the year, March, but people typically get up to 60 malaria-transmitting mosquito bites per month in August and September, when the rainy season peaks.

A total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control. Each volunteer received three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season. As expected, all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signaling that they had prior exposure to malaria parasites.

Those who received the candidate vaccine tolerated it very well and experienced a significant boost (up to a sixfold rise) in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.

Other collaborators included scientists from Walter Reed Army Institute of Research, Silver Spring, Maryland; the U.S. Agency for International Development, Washington, DC; and GlaxoSmithKline Biologicals, in Rixensart, Belgium.

ARTICLE: MA Thera et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a Phase 1 randomized controlled trial. PLoS ONE DOI: 10.1371/journal.pone.0001456 (2008). The paper will be available from the journal after 8 pm. ET Jan. 22, 2008 at: http://www.plosone.org/doi/pone.0001465

WHO: Anthony S. Fauci, M.D., Director, NIAID, and Lee Hall, M.D., Ph.D., Chief, NIAID Parasitology and International Programs Branch, are available to discuss this research and NIAID’s research projects in malaria vaccine development.

CONTACT: To schedule interviews, contact Anne A. Oplinger in the NIAID Office of Communications and Government Relations at 301-402-1663 or aoplinger@niaid.nih.gov.

NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases.

Anne A. Oplinger | EurekAlert!
Further information:
http://www.nih.gov
http://www.niaid.nih.gov

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>